Edition:
United States

Aeterna Zentaris Inc (AEZS.OQ)

AEZS.OQ on NASDAQ Stock Exchange Capital Market

2.08USD
15 Dec 2017
Change (% chg)

$-0.14 (-6.31%)
Prev Close
$2.22
Open
$2.23
Day's High
$2.23
Day's Low
$2.06
Volume
101,183
Avg. Vol
67,865
52-wk High
$4.25
52-wk Low
$0.78

Latest Key Developments (Source: Significant Developments)

Aeterna Zentaris Announces Departure Of Interim Chief Financial Officer
Friday, 8 Dec 2017 08:00am EST 

Dec 8 (Reuters) - Aeterna Zentaris Inc ::AETERNA ZENTARIS ANNOUNCES DEPARTURE OF INTERIM CHIEF FINANCIAL OFFICER.AETERNA ZENTARIS INC - DEPARTURE OF COMPANY'S INTERIM CHIEF FINANCIAL OFFICER, JEFFREY WHITNELL, EFFECTIVE DECEMBER 7, 2017.AETERNA ZENTARIS INC - COMMENCED A SEARCH FOR WHITNELL'S REPLACEMENT AS PRINCIPAL FINANCIAL OFFICER.  Full Article

Aeterna Zentaris’ MAA for Macrilen™ accepted by EMA
Monday, 27 Nov 2017 04:41pm EST 

Nov 27 (Reuters) - Aeterna Zentaris Inc ::AETERNA ZENTARIS’ MARKETING AUTHORIZATION APPLICATION FOR MACRILEN™ (MACIMORELIN) FOR EVALUATION OF ADULT GROWTH HORMONE DEFICIENCY ACCEPTED BY EUROPEAN MEDICINES AGENCY.AETERNA ZENTARIS INC - ‍MAA FOR USE OF MACRILEN FOR EVALUATION OF ADULT GROWTH HORMONE DEFICIENCY BEEN ACCEPTED BY EMA FOR REGULATORY REVIEW​.  Full Article

Aeterna Zentaris reports Q3 loss per share of $0.61
Wednesday, 8 Nov 2017 05:05pm EST 

Nov 8 (Reuters) - Aeterna Zentaris Inc :Aeterna Zentaris reports third quarter 2017 financial and operating results.Q3 loss per share $0.61.  Full Article

Aeterna Zentaris reports departure of finance and chief accounting officer
Friday, 1 Sep 2017 04:30pm EDT 

Sept 1 (Reuters) - Aeterna Zentaris Inc ::Aeterna Zentaris announces departure of vice president, finance & chief accounting officer.Aeterna Zentaris - ‍ departure of co's vice president, finance & chief accounting officer, Geneviéve Lemaire, effective on or before sept 30, 201​.Aeterna Zentaris Inc - ‍ commenced a search for Lemaire's replacement as principal financial officer​.  Full Article

Aeterna Zentaris reports Q2 loss per share $0.18
Thursday, 10 Aug 2017 06:09pm EDT 

Aug 10 (Reuters) - Aeterna Zentaris Inc -:Aeterna Zentaris reports second quarter 2017 financial and operating results.Q2 loss per share $0.18.Aeterna Zentaris Inc - ‍is conducting a strategic review of its plans​.Aeterna Zentaris Inc - ‍restructuring program of frankfurt, germany operations was approved by company and german work council​.Aeterna Zentaris Inc - ‍total cost of restructuring program is expected to be approximately $2.0 million​.Aeterna Zentaris Inc - ‍most of restructuring costs are expected to be paid in financial year ending december 31, 2018​.Aeterna Zentaris-‍formed special committee of independent directors to consider & evaluate various strategic and financing alternatives available to co.Aeterna Zentaris Inc - ‍three sales representatives and one sales-manager position were eliminated at quarter-end as part of sales force optimization​.Aeterna Zentaris Inc- ‍goal is to be prepared to launch macrilen in united states in q1 of 2018​.Aeterna Zentaris-restructuring program should lead to annual savings of about $2.5 million following complete implementation expected to be at end of 2018​.  Full Article

David Dodd responds to claim filed by Aeterna Zentaris
Friday, 4 Aug 2017 02:47pm EDT 

Aug 4 (Reuters) - David Dodd::David Dodd, former CEO of Aeterna Zentaris, responds to claim filed by Aeterna Zentaris against him & Philip Theodore​.Says intends to continue to serve as director of Aeterna.Says Dodd and Theodore consider Aeterna's claim to be "without merit", and intend to defend against it​.  Full Article

Aeterna Zentaris says ‍strategic review committee will be chaired by Carolyn Egbert, and includes Michael Cardiff​
Thursday, 20 Jul 2017 05:00pm EDT 

July 20 (Reuters) - Aeterna Zentaris Inc :Aeterna Zentaris forms strategic review committee and appoints Michael Ward as CEO.Aeterna Zentaris Inc - ‍Strategic review committee will be chaired by Carolyn Egbert, and includes Michael Cardiff​.David A. Dodd has ceased to be company's president and CEO with immediate effect..Board of directors of company has appointed Michael Ward as company's chief executive officer.Aeterna Zentaris Inc - ‍Formed a special committee to consider and evaluate various strategic and financing alternatives available to company​.Aeterna Zentaris Inc - ‍Special committee to evaluate alternatives including considering and recommending changes to co's management and governance​.  Full Article

Aeterna Zentaris resubmits NDA for Macrilen for the evaluation of growth hormone deficiency in adults
Friday, 30 Jun 2017 09:15am EDT 

June 30 (Reuters) - Aeterna Zentaris Inc :Aeterna Zentaris resubmits NDA for Macrilen™ for the evaluation of growth hormone deficiency in adults.Aeterna Zentaris - "Believe FDA review period of NDA will be up to 6 months, setting stage for potential approval of product late in 2017, early in 2018".Aeterna Zentaris Inc - Focus is to be prepared to launch Macrilen in Q1 of 2018.  Full Article

Aeterna Zentaris qtrly loss per share $0.31
Monday, 8 May 2017 04:30pm EDT 

May 8 (Reuters) - Aeterna Zentaris Inc ::Aeterna Zentaris reports first quarter 2017 financial and operating results.Aeterna Zentaris Inc - qtrly revenue $261,000 versus $242,000; qtrly loss per share $0.31.Aeterna Zentaris Inc - do not anticipate conducting clinical trials of zoptrex with respect to any other indications.Aeterna Zentaris Inc - co's focus has now shifted entirely to filing new drug application for macrilen.  Full Article

Aeterna Zentaris says ZoptEC Phase 3 clinical study of Zoptrex did not achieve primary endpoint
Monday, 1 May 2017 08:00am EDT 

May 1 (Reuters) - Aeterna Zentaris Inc :Aeterna Zentaris announces that ZoptEC Phase 3 clinical study of Zoptrex did not achieve its primary endpoint.Aeterna Zentaris Inc - company expects to submit Macrilen NDA in Q3 of 2017.Aeterna Zentaris Inc - Zoptrex generally performed no better than comparator drug with respect to secondary efficacy endpoints.Aeterna Zentaris - median overall survival period for patients treated with Zoptrex was 10.9 months which is not a statistically significant.Aeterna Zentaris - intention to submit Macrilen NDA in Q3 of 2017 and, if product receives FDA approval, to commercially launch product in Q1 of 2018.  Full Article